LONDON, Feb 7, 2026, 20:00 GMT — The market is shut for the day.
- AstraZeneca finished the day in New York up 3.1% at $193.03, while the stock in London gained 0.9% to close at 14,104p.
- The company is set to report both fourth-quarter and full-year 2025 numbers on Tuesday, Feb. 10.
- After a stretch of regulatory updates and pipeline news, investors have their eyes on the 2026 outlook.
AstraZeneca PLC (AZN) wrapped up Friday with its New York shares gaining 3.1% to finish at $193.03, then tacking on another 0.7% in after-hours moves to reach $194.40.
Markets are closed Saturday. Eyes now turn to AstraZeneca’s full-year and fourth-quarter 2025 results, slated for Tuesday. The company plans to release numbers at 07:00 GMT, then host an investor webcast at 11:45 GMT.
The stock heads into earnings after a stretch without much in the way of new announcements Friday, so guidance is carrying extra weight this time. For AstraZeneca, speed is the thing—investors want to see if growth from its latest cancer and specialty drugs can stay ahead of declines from legacy products.
AstraZeneca AZN.L finished Friday’s session in London at 14,104 pence, advancing 0.9%.
Hargreaves Lansdown analysts pointed to consensus estimates calling for revenue to climb 8.4% in 2025, hitting $58.6 billion, and operating profit up 7.7% to $18.3 billion. As for the outlook, they flagged “guidance for 2026 and beyond” as the real test, stressing that investors want “assurance needed on future targets”. Hargreaves Lansdown
AstraZeneca’s results are set to arrive just days after it started trading ordinary shares on the New York Stock Exchange, a move that syncs up its listings in New York, London and Stockholm. The company is dropping its Nasdaq depositary-share programme. Chair Michel Demaré said this marks “the start of an exciting new period” and highlighted AstraZeneca’s $80 billion revenue target for 2030. AstraZeneca
Regulatory hurdles remain a factor. The U.S. Food and Drug Administration sent a complete response letter earlier this week, blocking approval for the current filing of a subcutaneous version of Saphnelo—AstraZeneca’s lupus drug that would make at-home dosing possible. AstraZeneca now sees a decision possibly pushed into the first half of 2026. Saphnelo generated $483 million during the first nine months of 2025. Under its licensing agreement, AstraZeneca pays U.S. royalties to Bristol Myers Squibb.
AstraZeneca and Daiichi Sankyo notched a win: the FDA gave Datroway a Priority Review as a first-line treatment for metastatic triple-negative breast cancer. That status means a quicker review clock. The companies expect an FDA decision sometime in the second quarter of 2026. “Underscores the impact” of the trial, said AstraZeneca oncology R&D chief Susan Galbraith. AstraZeneca
AstraZeneca picked up a key endorsement in Europe as the European Medicines Agency’s CHMP committee backed its Imfinzi perioperative regimen for early-stage gastric and gastroesophageal cancers. Josep Tabernero, the trial’s lead investigator, called the committee’s view “a major step forward” for patients. AstraZeneca
Competition remains fierce here. New cancer drugs don’t see smooth launches, with payers moving fast to pressure prices if the medical benefits look similar. What matters just as much as results, frankly, is whether the company has a straightforward regulatory track and a solid plan to sell.
The rally ahead of earnings sets up the stock for a potentially bigger swing. If margins disappoint, guidance for 2026 comes in soft, or there’s fresh trouble with the Saphnelo self-injection rollout, shares could drop quickly.
Tuesday brings the full-year numbers and a management webcast—investors are set to dig for specifics around 2026 growth, profitability targets, and how the pipeline is shaping up. After that, focus shifts to the looming second-quarter FDA verdict on Datroway, plus any signals about the Saphnelo resubmission process.
